Rabbit Anti-Human Thymocyte Immunoglobulin

This article summarizes several clinical trials investigating the use of rabbit anti-human thymocyte immunoglobulin (rATG) in transplant patients. rATG is an immunosuppressive medication used to prevent rejection in organ and stem cell transplants. The trials examine rATG’s efficacy and safety for various types of transplants, including kidney, stem cell, and bone marrow transplants. Researchers are studying optimal dosing, timing, and combinations with other medications to improve transplant outcomes and reduce complications.

What is RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN?
How does it work?
What is it used for?
How is it administered?
What are the potential side effects?
Precautions and contraindications
Ongoing research

What is RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN?

RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN, also known as anti-thymocyte globulin (ATG) or by its brand name Thymoglobuline, is a medication derived from rabbit blood^[1]. It belongs to a class of drugs called immunosuppressants, which are used to reduce the activity of the immune system^[2].

How does it work?

ATG works by targeting and depleting T-cells, which are a type of white blood cell responsible for immune responses. By reducing the number of T-cells, ATG helps to suppress the immune system’s activity^[3]. This is particularly useful in situations where the immune system needs to be controlled, such as during organ transplantation or in the treatment of certain autoimmune diseases.

What is it used for?

RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN is primarily used in the following medical situations:

Organ Transplantation: It is commonly used to prevent and treat rejection in kidney transplant patients^[2].
Stem Cell Transplantation: ATG is used in the preparation for hematopoietic stem cell transplants, particularly in patients with blood cancers like acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)^[3].
Graft-versus-Host Disease (GvHD) Prevention: It helps prevent GvHD, a condition where transplanted cells attack the recipient’s body^[1].
Treatment of Aplastic Anemia: ATG is sometimes used in the treatment of severe aplastic anemia, a condition where the bone marrow doesn’t produce enough new blood cells^[4].

How is it administered?

RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN is typically administered as an intravenous (IV) infusion in a hospital setting. The dosage and duration of treatment can vary depending on the specific medical condition and individual patient factors. Common dosing regimens include:

For kidney transplantation: 1.5 mg/kg/day for 4-7 days^[2]
For stem cell transplantation: 2.5 mg/kg/day for 3 days or 5 mg/kg total over 2-3 days^[3]

The medication is usually given under close medical supervision, and patients are monitored for any immediate reactions during and after the infusion.

What are the potential side effects?

As with any medication, RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN can cause side effects. Some of the most common include:

Fever and chills
Nausea and vomiting
Headache
Diarrhea
Low blood pressure
Increased risk of infections
Allergic reactions

More serious side effects can include severe infections, blood disorders, and in rare cases, the development of certain cancers. It’s important to discuss all potential risks with your healthcare provider^[4].

Precautions and contraindications

RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN should not be used in patients with:

Known hypersensitivity to rabbit proteins
Active, uncontrolled infections
History of anaphylaxis to ATG or any of its components

Caution should be exercised in patients with a history of malignancies, and in those who are pregnant or breastfeeding. Regular monitoring of blood counts and liver function is typically required during treatment^[2].

Ongoing research

Several clinical trials are currently exploring new applications and optimizing the use of RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN. These include:

Comparing different dosing regimens in stem cell transplantation^[1]
Investigating its use in elderly patients with blood cancers^[5]
Studying its effectiveness in preventing graft-versus-host disease in pediatric patients^[6]

These ongoing studies aim to further improve the efficacy and safety of ATG in various medical conditions.

Trial Focus	Patient Population	Key Objectives	rATG Dosing
Preventing GVHD in stem cell transplants	Children and adults undergoing stem cell transplantation	Characterize pharmacokinetics of rATG and evaluate impact on GVHD prevention	5-20 mg/kg total over 2-5 days
Kidney transplant induction therapy	Adult kidney transplant recipients	Compare rATG to basiliximab for preventing acute rejection	1.5 mg/kg/day for 3-7 days
Reduced intensity stem cell transplant	Patients with hematological malignancies	Assess rATG exposure and impact on outcomes	5 mg/kg total over 2-3 days
GVHD prevention in haploidentical transplants	Elderly patients with hematological malignancies	Evaluate low-dose rATG for enhanced GVHD prophylaxis	1 mg/kg total on day 30-35 post-transplant
Induction therapy comparison	Adult kidney transplant recipients	Compare rATG to siplizumab for safety and efficacy	1.5 mg/kg/day for 3 days

Trial Focus

Patient Population

Key Objectives

rATG Dosing

Preventing GVHD in stem cell transplants

Children and adults undergoing stem cell transplantation

Characterize pharmacokinetics of rATG and evaluate impact on GVHD prevention

5-20 mg/kg total over 2-5 days

Kidney transplant induction therapy

Adult kidney transplant recipients

Compare rATG to basiliximab for preventing acute rejection

1.5 mg/kg/day for 3-7 days

Reduced intensity stem cell transplant

Patients with hematological malignancies

Assess rATG exposure and impact on outcomes

5 mg/kg total over 2-3 days

GVHD prevention in haploidentical transplants

Elderly patients with hematological malignancies

Evaluate low-dose rATG for enhanced GVHD prophylaxis

1 mg/kg total on day 30-35 post-transplant

Induction therapy comparison

Adult kidney transplant recipients

Compare rATG to siplizumab for safety and efficacy

1.5 mg/kg/day for 3 days

Ongoing Clinical Trials on Rabbit Anti-Human Thymocyte Immunoglobulin

Glossary

Acute Graft-versus-Host Disease (aGVHD): A complication that can occur after stem cell or bone marrow transplant where the donor cells attack the recipient's body. It typically occurs within 100 days of transplant.
Allogeneic: Referring to cells, tissues, or organs transplanted from a genetically non-identical donor of the same species.
Biopsy-Proven Acute Rejection (BPAR): Rejection of a transplanted organ that is confirmed through examination of a tissue sample under a microscope.
Chronic Graft-versus-Host Disease (cGVHD): A long-term complication of stem cell or bone marrow transplant where donor cells attack the recipient's body, typically occurring more than 100 days after transplant.
Donor-Specific Antibodies (DSA): Antibodies in the transplant recipient that specifically target the donor's human leukocyte antigens (HLAs), potentially leading to rejection.
Graft-versus-Host Disease (GVHD): A condition where donor cells attack the recipient's body after a stem cell or bone marrow transplant.
Haploidentical: A type of transplant where the donor is a half-match for the recipient, typically a parent, child, or sibling.
Hematopoietic Stem Cell Transplantation (HSCT): A procedure that replaces damaged or diseased bone marrow with healthy stem cells, used to treat various blood and immune system disorders.
Human Leukocyte Antigen (HLA): Proteins on cell surfaces that help the immune system identify which cells belong in the body and which do not.
Immunosuppression: The intentional reduction of the body's immune response, typically to prevent rejection of transplanted organs or tissues.
Non-Relapse Mortality (NRM): Deaths occurring after transplantation that are not related to the recurrence of the original disease.
Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
Pharmacodynamics (PD): The study of the biochemical and physiological effects of drugs on the body, including their mechanisms of action and relationship between drug concentration and effect.
Reduced Intensity Conditioning (RIC): A less aggressive form of pre-transplant treatment that uses lower doses of chemotherapy and/or radiation to prepare the body for a stem cell transplant.
T cells: A type of white blood cell that plays a central role in the immune response, including the rejection of transplanted organs or tissues.

References

http://clinicaltrials.eu/trial/study-on-how-rabbit-anti-human-thymocyte-immunoglobulin-helps-prevent-graft-versus-host-disease-in-children-and-adults-undergoing-stem-cell-transplants/
http://clinicaltrials.eu/trial/study-on-preventing-rejection-in-kidney-transplant-patients-using-rabbit-anti-human-thymocyte-immunoglobulin-and-basiliximab/
http://clinicaltrials.eu/trial/study-on-fludarabine-melphalan-and-atg-for-patients-with-blood-cancer-undergoing-reduced-intensity-stem-cell-transplantation/
http://clinicaltrials.eu/trial/study-on-siplizumab-and-rabbit-anti-thymocyte-globulin-for-preventing-rejection-in-new-kidney-transplant-patients/
http://clinicaltrials.eu/trial/study-on-enhanced-gvh-prevention-in-elderly-patients-with-blood-cancer-using-rabbit-anti-human-thymocyte-immunoglobulin-during-stem-cell-transplantation/
http://clinicaltrials.eu/trial/study-on-allogeneic-stem-cell-transplantation-for-children-and-adolescents-with-acute-lymphoblastic-leukemia-using-etoposide-treosulfan-and-thiotepa/

#1 Clinical Trials Search in Europe